Zhecheng firms overcome pet vaccine R&D challenges

On August 7, automated equipment was running efficiently in the production workshop of Shangqiu Melan Bioengineering Co. This company, which has been deeply cultivating in the field of animal health products, has been actively laying out the domestic pet market in recent years, and the research and development of its “Cat Triple Inactivated Vaccine” has made key progress in spite of many difficulties. Now, the company is increasing its investment with greater determination, taking reform and innovation as the driving force, devoting itself to further optimizing its products, promoting high-quality development in continuous exploration and innovation, carrying out the spirit of the Third Plenary Session of the 20th CPC Central Committee in practical action, deepening the reform, and contributing to the development of the industry.

Shangqiu Melan Bio-engineering Co., Ltd. is a company specializing in the research and development, production, sales and technical service of animal health care products, with independent research institutions and pharmaceutical industrial parks, and more than 300 kinds of products covering 4 plates of veterinary pharmaceutical preparations, veterinary biologics, traditional Chinese medicines extracts and pet medicines. In the animal health care market, scientific and technological innovation is crucial. The enterprise knows that only through continuous innovation can it meet the market demand for products with high efficiency, safety and advanced technology application.

“For our enterprise, scientific and technological innovation is not only the core means to improve product quality and performance, but also a powerful weapon to develop new markets and meet the changing needs of customers. By continuously investing in scientific and technological innovation, we are able to optimize the production process, improve production efficiency and reduce costs, thus enhancing the market competitiveness of our products; at the same time, scientific and technological innovation also prompts us to constantly push forward and develop more distinctive and differentiated products.” Chang Wenyu, assistant to the chairman of Shangqiu Melan Bioengineering Co.

In recent years, in the process of market layout and product adjustment and optimization, the company recognizes the rapid growth of the domestic pet market, and increases the capital invested in the research and development of pet vaccines year by year. However, successful R&D is not an easy task and faces many problems. The biggest challenge is the screening and optimization of strains. It is very difficult to find strains that are highly immunogenic, safe and able to cope with mutations. At the same time, ensuring the stability and efficacy of the vaccine in different environments and in individual cats was also a major challenge. In the face of these difficulties, the R&D team did not flinch, and through a large number of experiments and data analysis, adjusted the screening program, and finally found the ideal strain; in terms of stability, the team cooperated with a number of scientific research institutions, repeated simulation tests and improved the process, and successfully overcame the problem. Now, its “Cat Triple Inactivated Vaccine” has received clinical trial approval from the Ministry of Agriculture and Rural Development.

“The key to overcoming these difficulties lies in the professionalism and tenacity of our team. Our R&D team consists of a group of experienced, professional and passionate people who are not afraid to face difficulties and do not give up. At the same time, we also attach great importance to cooperation and communication, and actively share our experience and discuss problems with excellent research institutions and counterparts at home and abroad, so as to obtain more ideas and resources. Furthermore, the company's firm support for R&D work has provided sufficient protection in terms of funding and equipment, allowing the team to focus on overcoming difficulties without distractions.” Chang Wenyu said.

In addition, in order to ensure the research and development of “Cat Triple Inactivated Vaccine”, the company has made great efforts in the production process, technical equipment and the introduction of talents. In terms of production process, the company actively introduces the international advanced vaccine production process and optimizes and innovates it according to the actual situation, so as to ensure high efficiency and precision of production. In terms of technical equipment, we have invested heavily in the purchase of first-class automated production lines and high-precision testing equipment, which has greatly improved production efficiency and product quality stability. In terms of talent introduction, we have recruited top scientific research and production management experts in the industry, and set up a professional team with high quality and innovative spirit. It is this series of initiatives for the success of the product provides a strong guarantee.

“The company has spared no expense in purchasing advanced production equipment and testing instruments to provide hardware support for the application of new technologies, and encourages employees to participate in relevant training and learning to enhance their own technical level to adapt to new production requirements. At the same time, we have set up a special R&D fund, which is invested annually at a certain percentage increment to ensure sufficient funding for the exploration and introduction of new technologies.” Chang Wenyu said.

The next step, the company will continue to increase R & D investment, further optimize the performance of the vaccine, and work in strict accordance with the requirements of clinical trials to ensure the safety and effectiveness of the vaccine. At the same time, we will strengthen talent training and team building to provide solid talent support for the company's high-quality development.

“In the future, we will pay more attention to investment in science and technology, continuously introduce high-end talents to enrich the R&D team and inject fresh blood for innovation; increase the investment in R&D funds to carry out more in-depth research and explore more advanced technologies and processes. At the same time, we strengthen the cooperation with domestic and foreign scientific research institutions, keep abreast of the industry's cutting-edge dynamics, and apply the latest scientific and technological achievements to our products. We believe that through continuous investment in science and technology, we will be able to realize the mass production of our core vaccines, contribute more to the cause of pet health, and bring more significant impetus to the development of the local economy and industry.” Chang Wenyu said. (Henan Daily client reporter Li Fenghu Liu Mengke correspondent Song Zhenhao / text)